Subject: TRI
Novartis Canada's statement on CADTH draft recommendations for LEQVIO® (inclisiran)
MONTRÉAL, March 21, 2024 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).
These draft recommendations advise to not reimburse LEQVIO for the treatment of hypercholesterolemia for both the heterozygous familial hypercholesterolemia (HeFH) and non-familial hypercholesterolemia with atherosclerotic cardiovascular disease (ASCVD) populations.
As an organization, Novartis respects the process conducted by CADTH but at the same time holds a firm belief in the value that LEQVIO brings to patients, clinicians, and the healthcare system. Globally, LEQVIO is widely accessible in 94 countries,4 with public reimbursement in 31 countries,5 and has positively impacted over 178,000 patients.5
LEQVIO was first approved by Health Canada in 2021 based on clinical trials that demonstrated its efficacy to safely lower LDL cholesterol1,2,3 and received a positive funding recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) in 2021 for adults with heterozygous familial hypercholesterolemia (HeFH). Since its commercialization in 2022, LEQVIO has made a difference in the lives of more than 2,000 Canadian patients.
The draft recommendations are open for feedback from eligible stakeholders until April 5th, 2024. This feedback opportunity can be accessed through the CADTH website at Open Calls for Input and Feedback | CADTH.
Novartis Canada stands behind the potential of this innovative therapy and remains committed to dedicating efforts and striving for a positive outcome that benefits Canadians living with cardiovascular diseases.
Cardiovascular diseases (CVD), including heart disease, stroke and vascular cognitive impairment, are responsible for the loss of one life every five minutes,8 and is the second leading cause of death in Canada after cancer.14 In Canada, heart disease is the leading cause of hospitalization among Canadian women, aside from giving birth,15 and within the Canadian healthcare system, CVD accounts for $22 billion annually.8 The five-year prevalence of ASCVD in Canada ranges between 6.91%- 8.55% in adults.9,10 HeFH has an estimated prevalence of 1 in 250 to 311 individuals.11,12,13
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.
References:
1 ClinicalTrials.gov. ORION-9 (NCT NCT0397121). https://classic.clinicaltrials.gov/ct2/show/NCT03397121 1 | |
2ClinicalTrials.gov. ORION-10 (NCT NCT03399370). https://classic.clinicaltrials.gov/ct2/show/NCT03399370 | |
3 ClinicalTrials.gov. ORION-11 (NCT NCT03400800). https://classic.clinicaltrials.gov/ct2/show/ | |
4 Novartis Annual Report 2023. https://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2023.pdfhttps://www.novartis.com/sites/novartis_com/files/novartis-annual-report-2023.pdf | |
5 Novartis Data on file | |
6 Cadth.ca. https://www.cadth.ca/inclisiran-1 | |
7 Cadth.ca . https://www.cadth.ca/inclisiran-0 | |
8 2019 Heart & Stroke Report. https://www.heartandstroke.ca/articles/connected-by-the-numbers | |
9 Chen G, Farris MS, Cowling T, Colgan SM, Xiang P et al. (2019) Treatment and low-density lipoprotein cholesterol management in patients diagnosed with clinical atherosclerotic cardiovascular disease in Alberta. Can J Cardiol 35 (7): 884-891. | |
10 Mackinnon ES, Goeree R, Goodman SG, Rogoza RM, Packalen M et al. (2022) Increasing Prevalence and Incidence of Atherosclerotic Cardiovascular Disease in Adult Patients in Ontario, Canada From 2002 to 2018. CJC Open 4 (2): 206-213. | |
11 Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM et al. (2017) Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 7 (9): e016461. | |
12 Hu P, Dharmayat KI, Stevens CA, Sharabiani MT, Jones RS et al. (2020) Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation 141 (22): 1742-1759. | |
13 Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG (2020) Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 75 (20): 2553-2566. | |
15 Jaffer S, Foulds HJA, Parry M, Gonsalves CA, Pacheco C, Clavel MA, Mullen KA, Yip CYY, Mulvagh SL, Norris CM. The Canadian Women's Heart Health Alliance ATLAS on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women-Chapter 2: Scope of the Problem. CJC Open. 2020 Oct 15;3(1):1-11. doi: 10.1016/j.cjco.2020.10.009. PMID: 33458627; PMCID: PMC7801195. |
SOURCE Novartis Pharmaceuticals Canada Inc.
These press releases may also interest you
|
News published on and distributed by:
